Propanc Biopharma (NASDAQ:PPCB) experienced a dramatic surge in its stock price on Thursday, climbing more than 150% following the release of new preclinical data for its lead candidate, PRP, in pancreatic cancer. The announcement sent shares to $2.69 as of 11:41 AM ET, a 151.4% increase from Wednesday's close of $1.07. Trading volume exploded to 78.8 million shares, approximately 20 times the stock's typical daily activity.
The market's enthusiastic response underscores the significance of the preclinical findings. Propanc reported that intravenous administration of PRP three times per week resulted in an average tumor growth inhibition exceeding 90% in both orthotopic models and patient-derived xenografts of pancreatic ductal adenocarcinoma, a particularly aggressive form of the disease. Additionally, median survival was more than 2.5 times longer in treated animals compared to controls, and the therapy also reduced liver and peritoneal metastases. The company stated that the variation in tumor growth reached statistical significance at p<0.001.
While these results are encouraging, it is crucial to note that PRP remains in the preclinical stage. Efficacy has only been demonstrated in animal studies, and the therapy's effectiveness in humans is unproven. The company is preparing a Phase 1b study protocol for up to 40 patients with advanced solid tumors, with plans to submit an Australian clinical trial application in the fourth quarter. The initial trial will focus on safety, tolerability, and dosage, with early signs of activity as a secondary goal.
The stock's performance on Thursday was notable, opening at $3.51 and reaching a high of $4.32 before settling back. This volatility reflects the high-risk, high-reward nature of early-stage biotech investing, where preclinical data can trigger outsized moves. However, investors should be aware that outcomes from animal studies often fail to translate to human efficacy.
Propanc's financial position adds another layer of risk. As of March 31, the company held just $443,702 in cash, having consumed $4.08 million in operating cash over the previous nine months with no reported revenue. The most recent quarterly report showed a nine-month net loss of $14.29 million, and executives have warned of significant uncertainty regarding the company's ability to continue as a going concern.
Given the lack of a widely circulated Wall Street consensus on the stock, trial funding and potential dilution are critical considerations for investors. The company will likely need to raise additional capital to advance PRP into clinical trials, which could dilute existing shareholders. This, combined with the inherent risks of drug development, underscores the speculative nature of this investment.
PRP is a combination of two pancreatic proenzymes designed to limit recurrence and metastatic progression. While the preclinical data are promising, the path to commercialization is long and fraught with regulatory, manufacturing, and safety hurdles. Investors should weigh the potential upside against the substantial risks before making any decisions.
